2023. Steroid-Refractory Chronic Graft-versus-Host Disease Treated with Ruxolitinib: A Narrative Review of Symptom Burden and Return to Daily Life. Journal of Clinical Case Studies and Reviews. 4, 1 (Nov. 2023), 31–36. DOI:https://doi.org/10.5281/zenodo.22227762.